Ticker

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its unaudited condensed interim consolidated financial statements for the six-month period ended June 30, 2026, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise…

“Customers know that if they pause or slow down they run the risk of being way behind,” Chief Executive Chuck Robbins said.

Marvell benefits from exponential AI data center growth and leadership in 1.6T optical networking chips. Custom chip programs, including Microsoft Maia 300 and CXL memory expansion, are driving new revenue streams. Severe optical device supply tightness is supporting a 10-20% pricing hike through CY27, but the risk is that the impact on gross margins is probably priced in.

Company Highlights Operational Excellence, Available Capacity and Capital-Efficient Growth Strategy as Retailers Seek Reliable Supply Partners

The catalyst is Micron Technology (NASDAQ:MU | MU Price Prediction), whose stock has cooled sharply after a blistering multi-quarter run tied to AI memory demand.